| 1 | Title: Phase I study on the pharmacokinetics of intravaginal, self-administered artesunate vaginal |
|----|---|
| 2 | pessaries among women in Kenya. |
| 3 | |
| 4 | Short title: Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries |
| 5 | among women in Kenya. |
| 6 | |
| 7 | Authors: Chemtai Mungo, MD, MPH ^{1,2} ; Katherine Sorgi ¹ , Cirillus Ogollah, BSc, DipCM ⁴ , |
| 8 | Brenda Misiko ⁴ , Cynthia Cheserem ⁴ , George Githongo ⁴ , Jackton Omoto, MBChB, MMed ³ |
| 9 | |
| 10 | Affiliations |
| 11 | 1. Department of Obstetrics and Gynecology, University of North Carolina Chapel Hill, 321 |
| 12 | S Columbia St, Chapel Hill, North Carolina, 27599, USA. |
| 13 | 2. Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, 450 |
| 14 | West Dr, Chapel Hill, North Carolina, 27599, USA |
| 15 | 3. Department of Obstetrics and Gynecology, Maseno University School of Medicine, P.O, |
| 16 | Kisumu, Kenya |
| 17 | 4. Kenya Medical Research Institute, Busia Rd, Kisumu, Kenya |
| 18 | |
| 19 | |
| 20 | Corresponding Author: |
| 21 | Chemtai Mungo, MD, MPH, chemtai_mungo@med.unc.edu |
| 22 | |

23 Abstract (300-word max):

| 24 | Cervical cancer remains a significant global health issue, especially in low- and middle-income |
|----|--|
| 25 | countries (LMICs), where access to prevention and treatment is limited and women are at a |
| 26 | higher risk of cervical cancer. Artesunate, a widely available drug used to treat malaria, has |
| 27 | shown promise in treating human papillomavirus (HPV)-associated anogenital lesions including |
| 28 | high-grade cervical precancer, in a recent Phase I studies in the United States. Data on the |
| 29 | pharmacokinetics of artesunate following intravaginal use, and its implications on malaria |
| 30 | resistance, are lacking. |
| 31 | |
| 32 | Objectives: The primary objective of this study is to investigate the pharmacokinetics of |
| 33 | Artesunate (AS) and its active metabolite, dihydroartemisinin (DHA) following intravaginal use |
| 34 | at the dosing and frequency intended for cervical precancer treatment. A secondary objective is |
| 35 | to assess safety among study participants. |
| 36 | |
| 37 | Methods: We are conducting a single-arm, phase I trial with a sample size of 12 female |
| 38 | volunteers. Participants will self-administer artesunate vaginal pessaries in the study clinic daily |
| 39 | for 5 consecutive days. Participants will have their blood drawn prior to receiving the first dose |
| 40 | of artesunate on day one of the study and then will receive 8 blood draws on study day five, prior |
| 41 | to artesunate administration and at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and |
| 42 | 8 hours after pessary administration. Pharmacokinetic parameters of artesunate and DHA will be |
| 43 | calculated by way of quantitative analysis of with determination of maximum concentration |
| 44 | (Cmax), time to Cmax (Tmax), area under the plasma concentration versus time curve (AUC), |
| 45 | apparent clearance, and elimination half-life ($t1/2$). |

46

47 Keywords: pharmacokinetics, artesunate, dihydroartemisinin, intravaginal use, cervical48 precancer, malaria resistance

49

50 Introduction:

51 Cervical cancer is the second most common cancer in women globally, with a high 52 prevalence in low- and middle-income countries like Kenya. It is caused by human 53 papillomavirus (HPV) infection but can be prevented through vaccinations or early screening to 54 find precancerous changes in the cervix – also known as cervical intraepithelial neoplasia. While 55 these methods can prevent cervical cancer from developing in women, there are access and resource barriers, especially in LMICs. For instance, HPV vaccinations are new in Kenya and 56 57 other LMICs, and very few women under the age of 20 have been vaccinated. There are also cost 58 barriers and shortages in healthcare providers. In countries like Kenya and other LMICs where 59 there are few nurses and doctors, many women with cervical precancer are often referred to far 60 away facilities to access treatment and due to costs and other challenges, many are unable to 61 access the referral centers with providers who can offer treatment.

These barriers have led to researchers exploring the option of self-administered treatments for cervical precancer to overcome healthcare provider and healthcare resource shortages. One treatment being studied is an intravaginal pessary formulation of the drug Artesunate, which is often used to treat malaria. While a U.S. study has shown its safety and early efficacy for cervical precancer treatment,¹ it is unknown whether intravaginal use of artesunate vaginal inserts at the dosing and frequency used, may result in systemic exposure and hence have implications for malaria resistance. To fill this gap in the literature, this study seeks

to investigate the pharmacokinetics of intravaginal artesunate at the dose and frequency used inongoing cervical precancer treatment studies.

71

72 Intravaginal Artesunate for Cervical Precancer Treatment

73 Artesunate (AS), a World Health Organization (WHO) approved malaria drug, is being 74 explored as a potential topical therapy for cervical precancer as its safety and tolerability has long been well established.²⁻⁵ Growing evidence suggests its cytotoxic effects against numerous 75 76 cancer cell lines both *in vitro* and *in vivo* and have revealed its proposed mechanisms of action 77 include suppressing cell proliferation by inducing G1 and G2M phrase cell cycle arrest and 78 modulation of inflammatory pathways characteristic of uncontrolled proliferation and carcinogenesis.⁶⁻⁹ Ferroptosis, an iron-dependent cell death type, is thought to be a key 79 anticancer mechanism for HPV-infected cells.¹⁰ Cancer cells are highly proliferative, requiring a 80 heavy iron load which acts as a cofactor in synthesizing deoxyriboses before cell division.¹¹ 81 82 Development of both high-grade cervical intraepithelial neoplasia (CIN2/3), the precursor lesion 83 of cervical cancer, and cervical cancer are associated with the expression of two viral proteins in the HPV lifecycle, E6 and E7.¹² Epithelial cells that express either or both of these oncoproteins 84 also overexpress the transferrin receptor, and have been shown to have increased levels of 85 intracellular iron compared with normal cells.¹⁰ This observation has been exploited to 86 87 investigate whether preinvasive cervical cancer (CIN2/3), can be treated with Artesunate, which contains an endoperoxide bridge that reacts with intracellular ferrous iron to generate free 88 radicals, capable of inducing direct oxidative damage resulting in cell death.⁹ Given the 89 90 mechanism of action, artesunate may provide beneficial and therapeutic effects for intraepithelial 91 HPV disease.

| 92 | Several studies demonstrate the pro-apoptotic effects of Artesunate by activating the |
|-----|---|
| 93 | mitochondria-dependent pathway, including caspase-3/9 activation and cytochrome c release |
| 94 | from the mitochondria. ¹³ It induces autophagy in uterine corpus endometrial carcinoma cells and |
| 95 | elevates reactive oxygen species in human bladder cancer cells and hepatocellular carcinoma |
| 96 | cells. ¹⁴⁻¹⁶ Artesunate has demonstrated anti-angiogenic properties by downregulation VEGF and |
| 97 | angiopoietin-1 in myeloma cells. ¹⁷⁻¹⁹ Its reported anti-cancer effects involve the formation of |
| 98 | alkaline radicals through an endoperoxide bridge, reacting with intracellular ferrous iron and |
| 99 | leading to cell death. ²⁰ The overexpression of the transferrin receptor in cervical squamous cell |
| 100 | cancers and their precursors, ²¹ cervical intraepithelial neoplasia (CIN), prompted a study of |
| 101 | cytotoxic effects of dihydroartemisinin (DHA), the bioactive form of Artesunate, on |
| 102 | papillomavirus-expressing epithelial cells. ²² In vitro studies revealed that DHA had minimal |
| 103 | impact on normal cervical epithelial cells but had significantly induced cytotoxicity in HPV- |
| 104 | immortalized cervical cells. ²² Administered as a local treatment in a canine nonclinical model |
| 105 | with a 100% known tumor growth rate with HPV-infection, DHA (2.22 mg dissolved in 100 μl |
| 106 | dimethyl sulfoxide) reported to inhibit papillomavirus-induced tumor formation. In addition, |
| 107 | tumor-negative dogs developed antibodies against the HPV L1 capsid protein. ²² |
| | |

108

109 Safety for Intravaginal Use

In a multi-center dose-escalation phase 1 study in the United States, intravaginal
artesunate inserts (pessaries) were tested for safety, tolerability, and efficacy in women with
CIN2/3.¹ This "first-in-human" study demonstrated that intravaginal Artesunate for CIN2/3
treatment was safe, well tolerated, and resulted in self-limited adverse events that were graded I
and II. Reported AEs among participants who used 3 five-day artesunate cycles included chills

| 115 | and flu-like symptoms (n=3, grade 1), vaginal (yeast) infection (n=1, grade II), dizziness or |
|-----|---|
| 116 | headache (n=2, grade 1), non-infective cystitis (n=1, grade 2), vaginal pain or uterine cramping |
| 117 | (n=9, grade I), vaginal discharge (n=4, grade 1), vaginal pruritis (n=9, grade 1). In summary, 37 |
| 118 | drug-related AEs were observed in this Phase I trial, of which 34 (92%) were grade I, and 3 (8%) |
| 119 | were grade 2. Reported grade 2 adverse events included vaginal yeast infection ($n = 6$), bacterial |
| 120 | vaginosis (n = 2), vaginal inflammation (n = 2), urinary tract infection (n = 2), and noninfective |
| 121 | cystitis ($n = 1$). Adverse events that were determined to be unrelated to the study medication |
| 122 | included: anxiety, insomnia, suicidal ideation, vaginal twitching, fever, flu-like symptoms in a |
| 123 | patient who developed a cold, body itching, chills, and eczema flare. No subjects withdrew from |
| 124 | the study because of intolerable side effects, and all 28 subjects included in the modified- |
| 125 | intention-to-treat analyses were able to complete their designated dosing regimen. No grade 3 or |
| 126 | 4 adverse events were reported, and three subjects reported no noticeable side effects. Currently, |
| 127 | a randomized placebo-controlled phase II study of artesunate vaginal inserts in treatment of |
| 128 | CIN2/3 is enrolling subjects at several US sites, with no serious adverse events reported so far |
| 129 | (NCT04098744). Additionally, a phase II randomized trial of artesunate suppositories for |
| 130 | treating anal high-grade squamous intraepithelial lesions among HIV-negative individuals is |
| 131 | ongoing in the United States (NCT5555862) |

132

133 Summary of Artesunate Pharmacokinetics

The pharmacokinetics (PK) measures of artesunate (AS) and dihydroartemisinin (DHA)
following intravenous (IV), intramuscular (IM), oral and rectal administration have been well
described.²³ These PK parameters include maximum concentration of the drug in the blood
(Cmax), time to maximum concentration Cmax (Tmax), apparent clearance (CL/F) - the drug

138 concentration in the body in proportion to the rate of elimination, volume of distribution (V/F), 139 the area under the plasma concentration versus time curve (AUC) which expresses the total 140 amount of the drug in systemic circulation after administration, and half-life $(t_{1/2})$. IV 141 administration of AS quickly produces high maximum concentrations (Cmax) of AS, higher than 142 any other method of administration. One example of this can be seen in a study of adults with 143 uncomplicated malaria which compared AS and DHA levels following IV and IM 144 administration, Cmax values for AS when administered intravenously reached over 16,000 ng/mL while only reaching around 884mg/mL when administered intramuscularly.²⁴ Similarly, the 145 146 maximum concentration (Cmax) of AS and DHA peak quickly following IV administration, 147 followed by a rapid decline. The average half-life of AS following IV administration of less than 148 fifteen minutes in multiple studies, with an observed clearance range of 2-3 L/kg/hr and a volume range of 0.1-0.3 L/kg.²³ The hydrolysis of AS into DHA following IV administration is 149 150 similarly quick, with maximum DHA levels reached soon after IV AS administration. The Tmax 151 for DHA after IV administration was consistently less than 25 minutes according to the observed 152 studies with DHA clearance averaging between 0.5-1.5 L/kg/hr and volume averaging between 0.5-1.0 L/kg.²³ The AUC of AS following IV administration of 120 mg AS in adults ranged 153 between 876ng*hr/ml in healthy volunteers²⁵ and 1038 - 1269ng*hr/ml in those with malaria.²⁶ 154 155 The AUC of DHA following IV administration of 120 mg AS in adults ranged from 1850 ng*hr/ml in healthy volunteers²⁷ to 1845-2377ng*hr/ml in those with malaria.²⁸ 156 157 Compared to IV administration, IM administration produces lower peaks, longer half-life, 158 and higher volumes of distribution for AS, as well as delayed peaks for DHA. For example, AS 159 half-life following in IV administration is less than 15 minutes on average, compared to 25.2 to 48.2 minutes with IM administration.²³ Other parameters – in including DHA half-life, volume 160

of distribution, and clearance rates following IM administration resembled the values recorded
after IV administration in multiple studies, due to the high bioavailability, assessed by exposure
to DHA, associated with IM AS administration (>86%).²³ The AUC of AS following IM
administration of 120 mg AS in adults ranged between 856²⁹ - 999²⁵ng*hr/ml in those with
malaria. The AUC of DHA following IM administration of 120 mg of AS in adults with malaria
was 2474ng*hr/ml in one study.²⁵

167 When AS is administered orally, DHA peak concentrations (Cmax), AUC, and half-life 168 averages are all notably higher than comparable AS parameters. The average time to DHA Cmax 169 and half-life following oral AS administration (200 mg/day) are 2 hours, and 0.5-1.5 hours, respectively, compared to one hour and 20-45 minutes, respectively, for AS.²³ While a similar 170 171 pattern is seen following IV and IM administration, namely, elevated levels of DHA half-life and 172 AUC compared to AS, the difference are notable following oral administration. Also, while oral 173 administration of AS results in a higher DHA Cmax compared to AS, IV and IM administration 174 result in a notably higher AS Cmax than DHA Cmax. Morris et al (2011) points out that the 175 variations observed following oral administration are most likely attributed to AS functioning as 176 a "pro-drug" for DHA when ingested orally and in response to "first-pass or systemic metabolism."²³ Essentially, when AS is taken orally, it is converted to DHA at a greater extent 177 178 than when it is taken intravenously or intramuscularly. The AUC of AS and DHA in a study of 179 healthy adult volunteers taking 200mg AS daily for 5 days was 67 ng*hr/ml and 1158 ng*hr/ml 180 for AS & DHA, respectively, on Day 1, and 60 ng*hr/ml and 1300 ng*hr/ml for AS & DHA, respectively, on Day 5.³⁰ Similar Cmax parameters for AS were 67 ng/ml and 58 ng/ml on Day 1 181 182 and 5, respectively, and a pooled DHA Cmax of 654 ng/ml, demonstrating the absence of time-183 dependent artesunate pharmacokinetics in healthy subjects during 5-day oral administration of

200 mg artesunate.³⁰ The AUC of AS following oral administration of 200 mg AS in adults 184 ranged between 60-67ng*hr/ml in healthy volunteers³¹ and 310ng*hr/ml in those with malaria.³² 185 186 The AUC of DHA following oral administration of 200 mg of AS in adults ranged from 1158-1331 ng*hr/ml^{31,33} in healthy volunteers to 3027ng*hr/ml in those with malaria.³² Rectal AS 187 188 administration yields pharmacokinetic results similar to those obtained from oral administration, 189 with the exception of delayed AS Cmax and longer AS half-life. Compared to IV administration, 190 expectedly, both AS absorption and elimination are prolonged following rectal administration. 191 Following rectal administration of AS, Tmax average between 0.58-1.43 hours, with a half-life between 0.9-.95 hours.²³ These averages are based on three different studies: two studies 192 containing pediatric patients with uncomplicated falciparum malaria (10 - 20mg/Kg dosing)^{34,35} 193 194 and one study containing healthy Malaysian adults (200 mg rectal suppository, ~4mg/Kg dosing).³⁶ Following rectal dosing of a one-time 200 mg AS suppository in healthy adults 195 196 (similar to our planned dosing), a Cmax, Tmax, half-life and AUC of 448.5 ng/ml, 1.43 hours, 197 0.95 hours, and 796 ng*hr/ml of AS were observed, and Cmax, Tmax, half-life and AUC of 198 385.6 ng/ml, 1.80 hours, 1.21 hours, and 965 ng*hr/ml respectively of DHA were observed in healthy adults.³⁶ No data are available on rectal PK in adults with malaria as this route of 199 200 administration is not used to treat malaria in adults. The longer half-life of AS following rectal dosing (average 0.9-0.95 hrs) compared to IM (average 25.2 - 48.2 minutes), or IV (average less 201 than 5 minutes) may reflect absorption rate-limited elimination of AS.²³ As is expected given 202 203 that rectal AS administration avoids by-pass metabolism, the discrepancy in AS and DHA AUC 204 values (796 ng*hr/ml and 965 ng*hr/ml, respectively), is not as striking with rectal, as compared with oral administration of AS (119 ng*hr/ml and 1331 ng*hr/ml, respectively). ²³ Similar to oral 205 206 administration, both DHA Tmax and half-life values were higher than that of AS following rectal

207 administration.²³

208

209 Effect of malaria infection status on artesunate and DHA pharmacokinetics

210 Teja-Isavadharm et al., conducted a direct comparison of DHA pharmacokinetics following oral AS administration in healthy adults and falciparum malaria patients.³⁷ The 211 212 investigators found significantly higher AUC and Cmax of DHA in subjects with malaria as 213 compared to healthy subjects. Similar results were obtained by Binh et al in a study comparing the PK in eight patients with falciparum malaria and ten healthy subjects³⁸ Due to the small size 214 215 of both studies, definitive conclusion regarding differences in PK between healthy and infected subjects cannot be drawn.²⁷ However, as DHA clearance is dependent on hepatic blood flow, a 216 217 reduction in clearance, and consequently an increase in exposure associated with acute malaria infection, would be consistent with known DHA's PK properties.²⁷ 218

219

220 Malaria treatment and artemisinin resistance

221 Artemisinin-based combination therapies (ACTs) are recommended by the WHO as the first line treatment for uncomplicated Plasmodium Falciparum.³⁹ In ACTs, artemisinin quickly, 222 223 and drastically, reduces the majority of malaria parasites, with the partner drug clearing the remaining parasites to prevent recrudescence.^{40,41} Artemisinin resistance is defined as delayed 224 225 parasite clearance (following treatment with an artesunate monotherapy or ACT) observed as a 226 parasite clearance half-life greater than five hours or microscopic evidence of parasites on day three.⁴² This represents partial resistance. While artemisinin resistance alone does not necessarily 227 228 lead to malaria treatment failure, reduced efficacy of the artemisinin component places greater 229 demands on the partner drug to clear a larger parasite mass, jeopardizing future efficacy (WHO).

230 Examples of ACTs include artemether-lumefantrine, artesunate-amodiaguine, artesunate-231 mefloquine, among others. Standard ACTs regimen for uncomplicated malaria is an oral 3-day course. Most studies indicate that current ACTs recommended in national malaria treatment 232 policies remain effective, with an overall efficacy rate of greater than 95%.⁴³ 233 234 Artemisinin's act exceptionally fast against intra-erythrocytic asexual blood-stage malaria parasites, affecting up to 10,000- fold reductions in parasite burden every 48 hours.⁴⁴ The 235 236 primary genetic drivers of artemisinin resistance, both *in vitro* and *in vivo*, are point mutations in the P. falciparum Kelch13 (*PfK13*) gene during the early ring stage.^{45,46} These mutations allow a 237 238 subset of early ring-stage parasites to survive cell-cycle arrest brought on by artemisinin 239 exposure, enabling those parasites to reinitiate transcription and complete their intraerythrocytic developmental cycle once artemisinin is no longer present at inhibitory concentrations.⁴⁷ In vitro 240 241 resistance is routinely defined as greater than 1% survival of early ring-stage parasites exposed to 242 700nM dihydroartemisinin (DHA-the primary active metabolite of ART) for 6 hours, followed by drug-free culture incubation for a further 66 hours.⁴² The resistance mechanism appears to 243 244 involve a complex interplay of K13 protein abundance, hemoglobin endocytosis, and the parasite response to stress.^{42,48} 245

In Africa, several studies have identified a number of low-frequency Pfk13 mutations associated with delayed parasite clearance in four countries: Ghana, Rwanda, Uganda Tanzania.^{49,50} Mutations including M476I, P553L, R561H, P574L, C580Y and A675V, were observed at low frequencies under 5%.⁴⁹ For example, in Tanzania, mutations were found in two parasites from 764 samples in 2027 (0.3%)⁶, and one parasite from 422 samples in 2019 (0.2%).⁴⁹ Similarly in Uganda, one parasite was identified from 796 samples in 2018/2019 (0.1%).⁵¹ A 2021 study in Northern Uganda from 2017 to 2019 identified in vivo artemisinin

resistance (parasite clearance half-life >5 hours) in a total of 14 out of 240 patients who received intravenous artesunate.⁵¹ Of these 14 patients, 13 were infected with P. falciparum parasites with mutations in the A675V or C469Y allele in the kelch13 gene.⁴⁶

256 P. falciparum resistance to artemisinin has been documented in five countries in 257 Southeast Asia; Cambodia, Lao People's Democratic Republic, Myanmar, Thailand and Vietnam (WHO).⁴¹ With implementation of combination therapy, improvements to health systems and 258 259 surveillance systems to monitor first- and second-line treatment, the consequences of the 260 development of resistance to antimalarial medicines may be less severe today than what was 261 observed with chloroquine in the 1980s. If parasites develop reduced sensitivity to artemisinin, ACTS will continue to cure malaria, as long as the partner drug remains effective.⁴¹ To 262 263 overcome resistance, potential changes can be made to ACT. Some of these include 264 modifications such as extending the duration of the ACT course (currently 3 days for oral 265 treatment), alternating use of different ACT regimens, and addition of another antimalarial drug to the standard ACTs (triple-ACT).⁴¹ Additionally, adding a malaria vaccine (e.g. RTS, S 266 267 vaccine) to mass drug administration campaigns could enhance treatment efficacy and help 268 prevent further artemisinin resistance development.

269

270 Systemic Artesunate absorption and possible implications for developing resistance for 271 malaria treatment.

Although there is no available pharmacologic data on serum absorption following intravaginal artesunate administration, this study aims to address this gap. The direct application of artesunate to the cervical mucosa at the proposed dose of 200mg (≤ 4 mg/kg based on planned inclusion criteria of weight \geq 50 Kg) is unlikely to result in systemic absorption. This planned

| 276 | dosage is 2.5-fold lower than the approved rectal suppository dose (10mg/Kg). In contrast to the | |
|-----|--|--|
| 277 | rectal mucosa, which is highly vascular and comprised of single-cell layer of columnar | |
| 278 | epithelium making it highly permeable, the cervico-vaginal tissue has a thick, stratified | |
| 279 | squamous epithelial cell layer and is significantly less vascular, reducing its systemic | |
| 280 | absorption. ⁵² Similarly, due to the rapid rate of elimination of Artesunate's active metabolite, ⁵³ | |
| 281 | no systemic accumulation is expected of Artesunate or its active metabolite with intravaginal | |
| 282 | multi-day dosing in the context of cervicovaginal administration. | |
| 283 | | |
| 284 | Methods | |
| 285 | Study Objectives | |
| 286 | Primary Objective | |
| 287 | The primary objective is to determine the area under the plasma concentration versus the | |
| 288 | time curve (AUC) of DHA following five consecutive days of self-administration of Artesunate | |
| 289 | vaginal inserts among healthy women living in Kenya | |
| 290 | | |
| 291 | Secondary Objectives | |
| 292 | 1. Determine the area under the plasma concentration versus time curve (AUC) of | |
| 293 | Artesunate (AS) following five consecutive days of self-administration of 200mg | |
| 294 | Artesunate vaginal inserts (pessaries) among healthy women in Kenya | |
| 295 | 2. Determine the maximum concentration of Artesunate (AS) (Cmax) following five | |
| 296 | consecutive days of self-administration of 200mg Artesunate vaginal inserts (pessaries) | |
| 297 | among healthy women in Kenya | |

| 298 | 3. | Determine the maximum concentration of dihydroartemisinin (DHA) (Cmax) following |
|-----|----|---|
| 299 | | five consecutive days of self-administration of 200mg Artesunate vaginal inserts |
| 300 | | (pessaries) among healthy women in Kenya |
| 301 | 4. | Determine the time to maximum concentration (Tmax) of Artesunate (AS) following five |
| 302 | | consecutive days of self-administration of 200mg Artesunate vaginal inserts (pessaries) |
| 303 | | among healthy women in Kenya |
| 304 | 5. | Determine the time to maximum concentration (Tmax) of dihydroartemisinin (DHA) |
| 305 | | following five consecutive days of self-administration of 200mg Artesunate vaginal |
| 306 | | inserts (pessaries) among healthy women in Kenya |
| 307 | 6. | Determine the half-life $(t_{1/2})$ of Artesunate (AS) following five consecutive days of self- |
| 308 | | administration of 200mg Artesunate vaginal inserts (pessaries) among healthy women in |
| 309 | | Kenya |
| 310 | 7. | Determine the half-life $(t_{1/2})$ of dihydroartemisinin (DHA) following five consecutive |
| 311 | | days of self-administration of 200mg Artesunate vaginal inserts (pessaries) among |
| 312 | | healthy women in Kenya |
| 313 | 8. | Determine the apparent clearance (CL/F) of Artesunate (AS) following five consecutive |
| 314 | | days of self-administration of 200mg Artesunate vaginal inserts (pessaries) among |
| 315 | | healthy women in Kenya |
| 316 | 9. | Determine the apparent clearance (CL/F) of dihydroartemisinin (DHA) following five |
| 317 | | consecutive days of self-administration of 200mg Artesunate vaginal inserts (pessaries) |
| 318 | | among healthy women in Kenya |

| 319 | 10. Determine the volume of distribution (V/F) of Artesunate (AS) following five |
|-----|---|
| 320 | consecutive days of self-administration of 200mg Artesunate vaginal inserts (pessaries) |
| 321 | among healthy women in Kenya |
| 322 | 11. Determine the volume of distribution (V/F) of dihydroartemisinin (DHA) following five |
| 323 | consecutive days of self-administration of 200mg Artesunate vaginal inserts (pessaries) |
| 324 | among healthy women in Kenya |
| 325 | 12. Investigate the safety of 5-day course of self-administered intravaginal artesunate vaginal |
| 326 | inserts (pessary) in women in Kenya |
| 327 | |
| 328 | Study design |
| 329 | This is a single-arm, nonrandomized, interventional phase I study among 12 women over |
| 330 | the age of 18 living in Kisumu, Kenya. Participants will self-administer 200 mg artesunate |
| 331 | vaginal inserts for five consecutive days with blood draws performed on day 1 (at baseline) and |
| 332 | on day 5. Day 1 will consist of one blood draw prior to first pessary use and day 5 will consist of |
| 333 | eight blood draws: one prior to final artesunate administration, at time 0, then at 15 minutes, 30 |
| 334 | minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after final artesunate pessary insertion. |
| 335 | |
| 336 | Study setting |
| 337 | This study will be conducted in Kisumu, Kenya at the Lumumba Sub-County Hospital |
| 338 | and at the Victoria Biomedical Research Institute. All study activities will take place at |
| 339 | Lumumba Sub-County Hospital except the day 5 study visit, which will take place at Victoria |
| 340 | Biomedical Research Institute. |
| 341 | |

342 Eligibility and Recruitment

343 Recruitment

- 344 Participants will be recruited from the general population within close proximity to the
- 345 study location in Kisumu County, which will include recruitment from local health facilities. The
- 346 study team will conduct local outreach activities and educational talks in the community to
- 347 harness interest in participating. If an individual is interested in participating, they will be
- 348 screened for eligibility and, if eligible, will provide their informed consent and will be briefed on
- 349 other study procedures before any study activities are performed.
- 350

351 Inclusion & exclusion criteria

- 352 Table 1: Inclusion and exclusion criteria for study participants
- 353

| Inclusion Criteria | Exclusion Criteria |
|---|--|
| Age 18 years to 65 years | Current pregnancy or breastfeeding status |
| Negative pregnancy test at screening | History of total hysterectomy |
| Weight ≥50 Kg at study entry* | Known allergy to Artesunate |
| Willingness to use contraception (hormonal or barrier) during the 5-day study dosing phase if of childbearing age (less than 50 years of age) | Have a medical comorbidity that in the opinion of the investigator would interfere with study participation |
| Ability and willingness to provide informed consent | Currently receiving artemisinin-based agents for malaria treatment or completed artemisinin-based treatment within the previous 3 days.** |
| Plan to reside in the study location during the study period | Male at birth |

Agrees for samples without identifiers to be shipped Current use of efavirenz antiretroviral outside of Kenya for testing

therapy

Positive malaria antigen test at screening

| 354 | *Justification for weight criteria: A minimum body weight of 50Kg will meet the planned |
|-----|--|
| 355 | artesunate dosing of \leq 4 mg/Kg for which excellent safety data is available. |
| 356 | **Based on dihydroartesunate (artesunate's active metabolite) half-life of between 0.5-1.5 |
| 357 | hours ²⁹ |
| 050 | |

358

Study procedures by visit 359

360 Pre-screening visit: Prior to enrollment of a participant, the study staff will pre-screen potential

361 participants at on-site or off-site locations. During these visits, study staff will explain the aspects

362 of the study to potential participants and will provide an explanation of eligibility requirements.

363

364 Screening/Enrollment visit: To begin the screening process, eligible participants will provide 365 their written informed consent for the study procedures. Once informed consent is obtained by 366 the study staff, the screening processes will begin, including a malaria antigen test to screen for 367 subacute malaria infection. If a participant tests positive for malaria, they will be referred for 368 treatment and considered screen failures, resulting in their discontinuation from participating in 369 the study. Given that the study is located in a malaria-endemic region, we have planned for a 370 high screening-to-enrollment ratio due to the likelihood of high rates of sub-clinical malaria. 371 Other screening and enrollment activities will involve the collection of basic demographic and 372 clinical data, study protocol training (including demonstration of intravaginal artesunate 373 application using a pelvic model), a limited physical and pelvic exam, a urine pregnancy test, and 374 a review of prohibited medications.

375

| 376 | Visit 1: On the same day or up to 14 days after the screening and enrollment visit, the participant |
|-----|--|
| 377 | will have their first study visit in the clinic. During this visit, eligibility will be confirmed, the |
| 378 | study protocol will be reviewed, and study staff will provide instructions on self-administering |
| 379 | artesunate. Additionally, the participant will have 2.5ml of blood drawn prior to their first |
| 380 | intravaginal self-administration of artesunate. Once self-administration of artesunate is complete, |
| 381 | the participant will insert a tampon and will be observed for 30 minutes prior to scheduling their |
| 382 | second visit on the following day. |
| | |

383

384 Visits 2-4: Visits 2, 3, and 4 must occur within 24 hours of each other so the study staff will 385 attempt to schedule the visits at approximately the same time each day. During these visits, the 386 study staff will review and record any adverse events (AE) using a standardized questionnaire 387 and the U.S. National Cancer Institute Common Terminology Criteria for Adverse Events 388 (CTCAE). If an adverse event is scored a grade II or worse, a pelvic exam will be performed. 389 After review of adverse events, and reiteration of prohibited medications, the participant will be 390 asked to again self-administer artesunate followed by insertion of a tampon. Once they are 391 observed for 30 minutes, the following visit will be scheduled.

392

393 Visit 5: Visit 5 will occur no more than 24 hours after visit 4, with the study staff aiming to 394 schedule it at approximately the same time as the prior day's visit. During this visit, the study 395 staff will review and record adverse events, conducting a pelvic exam as needed based on the 396 grading of observed AEs. After AEs are reviewed and a reiteration of prohibited medications is

| 397 | given, the participant will undergo their first 2.5ml blood draw of the visit before the insertion of |
|-----|---|
| 398 | artesunate. A peripheral cannula will be inserted at this time for subsequent blood draws. |
| 399 | Following the initial blood draw, the participant will perform their final self- |
| 400 | administration of artesunate, followed by the insertion of a tampon. Once the final self- |
| 401 | administration of artesunate is complete, 2.5ml of blood will be drawn after 15 minutes, 30 |
| 402 | minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours. After the last blood draw, participants |
| 403 | will be scheduled for the final visit, which will take place 4-10 days after visit 5. |
| 404 | |
| 405 | Visit 6: Visit 6 will occur 4-10 days after visit 5. During this visit, the study staff will review and |
| 406 | record adverse events since the last visit. Once AEs are recorded, the study staff will initiate |
| 407 | study termination and will provide the participant with any necessary financial reimbursement. |
| 408 | |
| 409 | Participant retention plan |
| 410 | To ensure retention in the study, participants will be required to sign an informed consent |
| 411 | document indicating their clear understanding of the study procedures, duration, and any other |
| 412 | factors that are necessary to understand before consenting to participate. Once enrolled and |
| 413 | consented, the study staff will consistently follow-up with participants to ensure they attend all |
| 414 | scheduled appointments, to report any adverse event experiences, and to answer any questions |

that the participant may have about their role in the study. To compensate for their time, each

416 participant will be reimbursed Kshs 1000 (approximately \$10) for each visit to account for

417 potential loss of wages and will be reimbursed for transport to and from the clinic. For the final

visit, which is expected to last up to 8 hours, participants will be reimbursed an additional Kshs

419 2,500 (\$25) for loss of wages. Participants may also receive refreshments during the visit

| 420 | depending on how long they are asked to wait. If there is ever concern that a participant is lost to |
|-----|--|
| 421 | follow-up, the study staff will make every effort to regain contact with the participant, whether |
| 422 | that be through calls or home visits. |
| 423 | |
| 424 | Statistical consideration |
| 425 | Sample size |
| 426 | This study will have a sample size of 12 healthy volunteers. |
| 427 | |
| 428 | Sample size justification |
| 429 | There are no prior data on the PK disposition of artesunate after intravaginal |
| 430 | administration and thus there is no data-related reason for the proposed sample size of 12 people. |
| 431 | This number was chosen as it is the standard number of patients evaluated in clinical PK studies |
| 432 | and it is adequate to perform pharmacokinetic plasma parameters of artesunate and DHA in order |
| 433 | to meet the study's primary objective. |
| 434 | |
| 435 | Data analysis |
| 436 | The data analysis plan for this study involves assessing the primary outcome, which is the |
| 437 | plasma concentration versus time curve (AUC) of dihydroartemisinin following five days of self- |
| 438 | administration of 200mg Artesunate pessaries. With the primary endpoint being Mean DHA |
| 439 | AUC (ng*hr/ml) with standard deviation on Day 5, statistical analysis will compare this mean |
| 440 | DHA AUC to historical studies after intravenous (IV), oral, and rectal administration among |
| 441 | adults with similar dosing. Results will be analyzed using a student t-test for one-sample |
| | |

443 The secondary outcomes include assessing the AUC of Artesunate, maximum 444 concentration of Artesunate and DHA (Cmax), time to reach maximum concentration (Tmax) for 445 Artesunate and DHA, half-life (t1/2) for Artesunate and DHA, apparent clearance of Artesunate 446 and DHA, and the volume of distribution of Artesunate and DHA. Statistical analysis of these 447 variables will include comparing data results to historical studies using relevant test materials. 448 The final outcome to be evaluated is the safety of the 5-day self-administration of Artesunate 449 vaginal inserts. This will be done by monitoring and reporting adverse events and categorizing 450 by their severity, with grade 3 or higher being considered severe. The proportion of participants 451 with a severe AE will be reported along the exact (Clopper-Pearson) one-sided upper 95% 452 confidence bounds. Safety among participants will be monitored and reported starting at the first 453 dose of artesunate.

454 This study will determine conventional pharmacokinetic parameters for Artesunate and 455 dihydroartemisinin (DHA). Parameters such as AUC, Cmax. Tmax, half-life, apparent clearance, 456 and the volume of distribution will be calculated using non compartmental analysis from the 457 plasma concentration-time data. AUC for Artesunate will be determined by linear trapezoidal 458 summation with extrapolation to infinity, starting from drug administration to the last observation. All parameters will be calculated using time in hours after the first drug 459 460 administration. With respect to DHA, AUC will be calculated to the last drug measurable time 461 point. The elimination rate constant (beta) will be calculated from the slope of the terminal phase 462 of the log concentration-time profile, and the elimination half-life (t1/2) calculated from the ratio 463 of ln 2/beta. Other PK parameters will be calculated using standard model-independent formulae.³⁹ The estimates of PK parameters for DHA will assume complete conversion of AS to 464

465 DHA as reported previously.³⁵ Data will be plotted graphically and analyzed using statistical
466 software. Data will be presented as mean with standard deviation (SD).

467

468 Discussion

469 Cervical cancer is preventable through vaccination against HPV, or screening for cervical 470 precancerous changes which can be treated. Access to cervical precancer treatment in low- and 471 middle-income countries is hindered by a shortage of trained healthcare provider and inadequate 472 health infrastructure. This results in a disproportionately high incidence and mortality rate from 473 this otherwise preventable disease. Use of self-administered topical therapies for cervical 474 precancer treatment, if found to be feasible and effective, can be transformative in increasing 475 access to secondary prevention of cervical cancer for marginalized women globally. Given 476 recent data demonstrating feasibility of topical Artesunate for treatment of HPV-associated 477 anogenital lesions, including vulvar and cervical precancer, it is imperative to understand the 478 pharmacokinetics of intravaginal use to inform studies using this drug in LMICs where malaria is 479 endemic.

480

481 Current Status:

- 482 The study opened for accrual in June 2024.
- 483

484 **Trial registration**:

485 The trial is registered under U.S Clinical trial registry (clinicaltrials.gov, NCT06263582).

- 487 List of abbreviations
- 488 LMICs: Low- and middle-income countries:

| 489 | AS: | Artesunate |
|-----|---|---|
| 490 | WHO: | World Health Organization |
| 491 | CIN2/3: | High-grade cervical intraepithelial neoplasia |
| 492 | HPV: | Human papillomavirus |
| 493 | DHA: | Dihydroartemisinin |
| 494 | PK: | Pharmacokinetics |
| 495 | IV: | Intravenous |
| 496 | IM: | Intramuscular |
| 497 | ACTs: | Artemisinin-based combination therapies |
| 498 | | |
| 499 | Declarations: | |
| 500 | Ethics approval and consent to participate | |
| 501 | This clinical trial has full ethics review board approval from the University of North Carolina | |
| 502 | Chapel Hill and the African Medical Research Foundation. Written informed consent will be | |
| 503 | obtained from | all study participants. |
| 504 | | |
| 505 | Consent for J | publication |
| 506 | Not applicable | 2. |
| 507 | | |
| 508 | Availability o | of data and materials |
| 509 | Not applicable | 2. |
| 510 | | |
| 511 | Competing in | nterests |
| 512 | "The authors | declare they have no competing interests." |
| 513 | | |
| 514 | Funding | |

| 515 | This research was supported by the Department of Obstetrics and Gynecology at University of | | |
|--------------------------|---|--|--|
| 516 | North Carolina-Chapel Hill. The content is solely the responsibility of the authors and does not | | |
| 517 | necessarily represent the official views of the National Institutes of Health. The study funders | | |
| 518 | have no role in the research. | | |
| 519 | | | |
| 520 | Authors' contributions | | |
| 521 | CM conceived and designed the study, providing subject matter expertise and overseeing all | | |
| 522 | aspects of protocol development. JO (Co-Principal Investigator) provided guidance on protocol | | |
| 523 | development and will lead protocol implementation in country. JO and CO (Co-Investigator) | | |
| 524 | contributed to study design, protocol implementation, and capacity building for providers. KS | | |
| 525 | contributed to manuscript writing. GG contributes to lab management activities including | | |
| 526 | collection, storage, and shipment of samples. BM and CC contribute to in-country study | | |
| 527 | coordination activities. All authors, in their respective roles, contributed to study and manuscript | | |
| 528 | preparation and have collectively approved the final manuscript. | | |
| 529 530 531 532 | Acknowledgements Not applicable. | | |
| 533 | References | | |
| 534 535 536 | Trimble CL, Levinson K, Maldonado L, et al. A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3). <i>Gynecol</i> <i>Oncol.</i> 2020;157(1):188-194. doi:10.1016/j.ygyno.2019.12.035 Warld Haelth Organization Weyl LUL and Concept for Transformation for Transformation. | | |
| 538 | 2. World Health Organisation. World Health Organization. Guidelines for Treatment of Malaria 3rd Edition : 2015 | | |
| 539 540 | Bar-Zeev N, White N. Evidence behind the WHO guidelines: Hospital Care for Children: efficacy and safety of artemisinin derivatives in children with malaria. <i>J Trop Pediatr</i>. 2006;52(2):78-82, doi:10.1003/tropai/fml005 | | |
| 542 543 | Johann-Liang R, Albrecht R. Safety evaluations of drugs containing artemisinin derivatives for the treatment of malaria. <i>Clin Infect Dis</i>. 2003;36(12):1626-1628. | | |
| 544 | doi:10.1086/375089 | | |
| 545 546 | 5. Nyaaba N, Andoh NE, Amoh G, et al. Comparative efficacy and safety of the artemisinin derivatives compared to quinine for treating severe malaria in children and adults: A | | |

| 547 | | systematic update of literature and network meta-analysis. <i>PLoS One</i> . |
|-----|------------|--|
| 548 | | 2022:17(7):e0269391_doi:10.1371/journal.pone.0269391 |
| 549 | 6. | Ellis T. Eze E. Raimi-Abraham BT. Malaria and Cancer: a critical review on the |
| 550 | 0. | established associations and new perspectives. <i>Infect Agent Cancer</i> , 2021:16(1):33. |
| 551 | | doi:10.1186/s13027-021-00370-7 |
| 552 | 7 | Ma Z. Woon CYN. Liu CG, et al. Repurposing Artemisinin and its Derivatives as |
| 553 | <i>,</i> . | Anticancer Drugs: A Chance or Challenge? Front Pharmacol 2021:12:828856 |
| 554 | | doi:10.3389/fnhar 2021 828856 |
| 555 | 8 | Jeong DE, Song HII Lim S, et al. Repurposing the anti-malarial drug artesunate as a |
| 556 | 0. | novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor |
| 557 | | growth metastasis and angiogenesis <i>Oncotarget</i> 2015:6(32):33046-33064 |
| 558 | | doi:10.18632/oncotarget.5422 |
| 559 | 9 | Efferth T. Sauerbrev A. Olbrich A. et al. Molecular modes of action of artesunate in |
| 560 | | tumor cell lines. <i>Mol Pharmacol</i> 2003:64(2):382-394 doi:10.1124/mol.64.2.382 |
| 561 | 10 | Siegel EM Patel N Lu B et al. Circulating biomarkers of iron storage and clearance of |
| 562 | 10. | incident human papillomavirus infection. <i>Cancer Epidemiol Biomarkers Prev</i> |
| 563 | | 2012·21(5)·859-865_doi:10.1158/1055-9965_EPI-12-0073 |
| 564 | 11. | Daniels TR. Bernabeu E. Rodríguez JA. et al. The transferrin receptor and the targeted |
| 565 | | delivery of therapeutic agents against cancer. <i>Biochim Biophys Acta</i> , 2012:1820(3):291- |
| 566 | | 317. doi:10.1016/i.bbagen.2011.07.016 |
| 567 | 12. | Schiffman M. Doorbar J. Wentzensen N. et al. Carcinogenic human papillomavirus |
| 568 | | infection. <i>Nat Rev Dis Primers</i> . 2016:2:16086. doi:10.1038/nrdp.2016.86 |
| 569 | 13. | Wong YK, Xu C, Kalesh KA, et al. Artemisinin as an anticancer drug: Recent advances |
| 570 | 10. | in target profiling and mechanisms of action. <i>Med Res Rev.</i> 2017:37(6):1492-1517. |
| 571 | | doi:10.1002/med.21446 |
| 572 | 14. | Zhou X, Chen Y, Wang F, et al. Artesunate induces autophagy dependent apoptosis |
| 573 | | through upregulating ROS and activating AMPK-mTOR-ULK1 axis in human bladder |
| 574 | | cancer cells. Chem Biol Interact. 2020;331:109273. doi:10.1016/j.cbi.2020.109273 |
| 575 | 15. | Zhang J, Zhou L, Xiang JD, Jin CS, Li MQ, He YY. Artesunate-induced ATG5-related |
| 576 | | autophagy enhances the cytotoxicity of NK92 cells on endometrial cancer cells via |
| 577 | | interactions between CD155 and CD226/TIGIT. Int Immunopharmacol. 2021;97:107705. |
| 578 | | doi:10.1016/j.intimp.2021.107705 |
| 579 | 16. | Yao X, Zhao CR, Yin H, Wang K, Gao JJ. Synergistic antitumor activity of sorafenib and |
| 580 | | artesunate in hepatocellular carcinoma cells. Acta Pharmacol Sin. 2020;41(12):1609- |
| 581 | | 1620. doi:10.1038/s41401-020-0395-5 |
| 582 | 17. | Gao F, Sun Z, Kong F, Xiao J. Artemisinin-derived hybrids and their anticancer activity. |
| 583 | | Eur J Med Chem. 2020;188:112044. doi:10.1016/j.ejmech.2020.112044 |
| 584 | 18. | Guan X, Guan Y. Artemisinin induces selective and potent anticancer effects in drug |
| 585 | | resistant breast cancer cells by inducing cellular apoptosis and autophagy and G2/M cell |
| 586 | | cycle arrest. J BUON. 2020;25(3):1330-1336. |
| 587 | 19. | Zhang B. Artemisinin-derived dimers as potential anticancer agents: Current |
| 588 | | developments, action mechanisms, and structure-activity relationships. Arch Pharm |
| 589 | | (Weinheim). 2020;353(2):e1900240. doi:10.1002/ardp.201900240 |
| 590 | 20. | Li D, Zhang J, Zhao X. Mechanisms and Molecular Targets of Artemisinin in Cancer |
| 591 | | Treatment. Cancer Invest. 2021;39(8):675-684. doi:10.1080/07357907.2021.1954190 |
| 592 | 21. | Anfosso L, Efferth T, Albini A, Pfeffer U. Microarray expression profiles of |

| 593 | | angiogenesis-related genes predict tumor cell response to artemisinins. |
|------------|----------|---|
| 594 | | <i>Pharmacogenomics J.</i> 2006;6(4):269-278. doi:10.1038/sj.tpj.6500371 |
| 595 | 22. | Disbrow GL, Baege AC, Kierpiec KA, et al. Dihydroartemisinin is cytotoxic to |
| 596 | | papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res. |
| 597 | | 2005;65(23):10854-10861. doi:10.1158/0008-5472.CAN-05-1216 |
| 598 | 23. | Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the |
| 599 | | clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin |
| 600 | | following intravenous, intramuscular, oral or rectal administration. <i>Malar J.</i> 2011;10:263. |
| 601 | | doi:10.1186/1475-2875-10-263 |
| 602 | 24. | Ilett KF, Batty KT, Powell SM, et al. The pharmacokinetic properties of intramuscular |
| 603 | | artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br J Clin |
| 604 | | <i>Pharmacol</i> , 2002:53(1):23-30. doi:10.1046/j.0306-5251.2001.01519.x |
| 605 | 25. | llett KF, Batty KT, Powell SM, et al. The pharmacokinetic properties of intramuscular |
| 606 | | artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br J Clin |
| 607 | | <i>Pharmacol.</i> 2002:53(1):23-30. doi:10.1046/i.0306-5251.2001.01519.x |
| 608 | 26 | KFI KTB SMP et al. The pharmacokinetic properties of intramuscular artesunate and |
| 609 | 20. | rectal dihydroartemisinin in uncomplicated falcinarum malaria <i>Br I Clin Pharmacol</i> |
| 610 | | 2002.53(1).23-30 doi:10.1046/10306-5251.2001.01519 X |
| 611 | 27 | Morris CA Duparc S Borghini-Fuhrer I Jung D Shin CS Fleckenstein I Review of the |
| 612 | 27. | clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin |
| 613 | | following intravenous intramuscular oral or rectal administration Malar I 2011:10:263 |
| 614 | | doi:10.1186/1475-2875-10-263 |
| 615 | 28 | Batty KT Thu IT Davis TM at al. A pharmacokinetic and pharmacodynamic study of |
| 616 | 20. | intravenous vs oral artesunate in uncomplicated falcinarum malaria. Br I Clin |
| 617 | | Dharmanol 1008:45(2):122 120 doi:10.1046/j.1265.2125.1008.00655 x |
| 619 | 20 | High TT Davis TME Chuong I. V. at al. Comparative pharmacolination of |
| 610 | 29. | intramuscular artequate and artemether in notionts with source falsingrum malaria |
| 620 | | Autimized A conta Chamathan 2004;48(11):4224,4220, doi:10.1128/AAC 48.11.4224 |
| 620 | | Anumicrob Agenis Chemoiner. 2004,46(11).4254-4259. doi:10.1126/AAC.46.11.4254- |
| 622 | 30 | 4259.2004 Diem Thuy I.T. Ngoc Hung I. Danh PT. Na-Bangchang K. Absence of time-dependent |
| 623 | 50. | artesunate pharmacokinetics in healthy subjects during 5 day oral administration <i>Fur I</i> |
| 624 | | <i>Clin Pharmacol</i> 2008:64(10):003 008 doi:10 1007/s00228 008 0506 6 |
| 024 625 | 21 | Diam Thuy I.T. Ngog Hung I. Danh PT. Na Bangahang K. Absance of time dependent |
| 025 | 51. | artequaste phermagoking in healthy subjects during 5 day oral administration. Fur I |
| 020 | | <i>Clin Dharmagol</i> 2009.64(10):002.009. doi:10.1007/S00229.009.0506.6 |
| 627 | 22 | Cun Pharmacol. 2008;04(10):995-998. doi:10.100//S00228-008-0500-0 |
| 628 | 32. | Krudsood S, Looareesuwan S, Tangpukdee N, et al. New fixed-dose artesunate- |
| 629 | | merioquine formulation against multidrug-resistant Plasmodium faiciparum in adults: a |
| 630 | | comparative phase lib safety and pharmacokinetic study with standard-dose nonlixed |
| 631 | | artesunate plus metioquine. Antimicrob Agents Chemother. 2010;54(9):3/30-3/3/. |
| 632 | 22 | doi:10.1128/AAC.0118/-09 |
| 633 | 33. | Navaratnam V, Mansor SM, Mordi MN, Akbar A, Abdullah MN. Comparative |
| 634 | | pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy |
| 635 | <u> </u> | volunteers. Eur J Clin Pharmacol. 1998;54(5):411-414. doi:10.1007/S002280050484 |
| 636 | 34. | Sirivichayakul C, Sabchareon A, Pengsaa K, et al. Comparative study of the effectiveness |
| 637 | | and pharmacokinetics of two rectal artesunate/oral mefloquine combination regimens for |
| 638 | | the treatment of uncomplicated childhood falciparum malaria. Ann Trop Paediatr. |

| 639 | | 2007;27(1):17-24. doi:10.1179/146532807X170466 |
|-----|-----|--|
| 640 | 35 | . Halpaap B, Ndjave M, Paris M, Benakis A, Kremsner PG. Plasma levels of artesunate |
| 641 | | and dihydroartemisinin in children with Plasmodium falciparum malaria in Gabon after |
| 642 | | administration of 50-milligram artesunate suppositories. Am J Trop Med Hyg. |
| 643 | | 1998;58(3):365-368. doi:10.4269/ajtmh.1998.58.365 |
| 644 | 36 | . Navaratnam V, Mansor SM, Mordi MN, Akbar A, Abdullah MN. Comparative |
| 645 | | pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy |
| 646 | | volunteers. Eur J Clin Pharmacol. 1998;54(5):411-414. doi:10.1007/s002280050484 |
| 647 | 37. | . Teja-isavadharm P, Watt G, Eamsila C, et al. Comparative pharmacokinetics and effect |
| 648 | | kinetics of orally administered artesunate in healthy volunteers and patients with |
| 649 | | uncomplicated falciparum malaria. Am J Trop Med Hyg. 2001;65(6):717-721. |
| 650 | | doi:10.4269/AJTMH.2001.65.717 |
| 651 | 38 | . Binh TQ, Ilett KF, Batty KT, et al. Oral bioavailability of dihydroartemisinin in |
| 652 | | Vietnamese volunteers and in patients with falciparum malaria. Br J Clin Pharmacol. |
| 653 | | 2001;51(6):541-546. doi:10.1046/J.1365-2125.2001.01395.X |
| 654 | 39 | . Guidelines for the Treatment of Malaria - PubMed. Accessed October 22, 2023. |
| 655 | | https://pubmed.ncbi.nlm.nih.gov/26020088/ |
| 656 | 40 | . Ward KE, Fidock DA, Bridgford JL. Plasmodium falciparum resistance to artemisinin- |
| 657 | | based combination therapies. Curr Opin Microbiol. 2022;69:102193. |
| 658 | | doi:10.1016/j.mib.2022.102193 |
| 659 | 41 | . Hanboonkunupakarn B, Tarning J, Pukrittayakamee S, Chotivanich K. Artemisinin |
| 660 | | resistance and malaria elimination: Where are we now? Front Pharmacol. 2022;13. |
| 661 | | doi:10.3389/FPHAR.2022.876282 |
| 662 | 42 | . Balikagala B, Fukuda N, Ikeda M, et al. Evidence of Artemisinin-Resistant Malaria in |
| 663 | | Africa. N Engl J Med. 2021;385(13):1163-1171. doi:10.1056/NEJMoa2101746 |
| 664 | 43 | . Mathenge PG, Low SK, Vuong NL, et al. Efficacy and resistance of different |
| 665 | | artemisinin-based combination therapies: a systematic review and network meta-analysis. |
| 666 | | Parasitol Int. 2020;74. doi:10.1016/J.PARINT.2019.04.016 |
| 667 | 44 | . Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA. Artemisinin Action and |
| 668 | | Resistance in Plasmodium falciparum. Trends Parasitol. 2016;32(9):682-696. |
| 669 | | doi:10.1016/J.PT.2016.05.010 |
| 670 | 45 | . Siddiqui FA, Liang X, Cui L. Plasmodium falciparum resistance to ACTs: Emergence, |
| 671 | | mechanisms, and outlook. Int J Parasitol Drugs Drug Resist. 2021;16:102-118. |
| 672 | | doi:10.1016/J.IJPDDR.2021.05.007 |
| 673 | 46 | . Mok S, Stokes BH, Gnädig NF, et al. Artemisinin-resistant K13 mutations rewire |
| 674 | | Plasmodium falciparum's intra-erythrocytic metabolic program to enhance survival. Nat |
| 675 | | Commun. 2021;12(1). doi:10.1038/S41467-020-20805-W |
| 676 | 47 | . Witkowski B, Amaratunga C, Khim N, et al. Novel phenotypic assays for the detection of |
| 677 | | artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo |
| 678 | | drug-response studies. Lancet Infect Dis. 2013;13(12):1043-1049. doi:10.1016/S1473- |
| 679 | | 3099(13)70252-4 |
| 680 | 48 | . Ward KE, Fidock DA, Bridgford JL. Plasmodium falciparum resistance to artemisinin- |
| 681 | | based combination therapies. Curr Opin Microbiol. 2022;69. |
| 682 | | doi:10.1016/J.MIB.2022.102193 |
| 683 | 49 | . Ndwiga L, Kimenyi KM, Wamae K, et al. A review of the frequencies of Plasmodium |
| 684 | | falciparum Kelch 13 artemisinin resistance mutations in Africa. Int J Parasitol Drugs |

685 *Drug Resist.* 2021;16:155-161. doi:10.1016/J.IJPDDR.2021.06.001

- 50. Moser KA, Madebe RA, Aydemir O, et al. Describing the current status of Plasmodium
 falciparum population structure and drug resistance within mainland Tanzania using
 molecular inversion probes. *Mol Ecol.* 2021;30(1):100-113. doi:10.1111/MEC.15706
- 51. Asua V, Conrad MD, Aydemir O, et al. Changing Prevalence of Potential Mediators of
 Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda. *J Infect Dis*.
 2021;223(6):985-994. doi:10.1093/INFDIS/JIAA687
- 52. Squier CA, Mantz MJ, Schlievert PM, Davis CC. Porcine vagina ex vivo as a model for
 studying permeability and pathogenesis in mucosa. *J Pharm Sci.* 2008;97(1):9-21.
 doi:10.1002/jps.21077
- 53. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. *Int J Parasitol.*2002;32(13):1655-1660. doi:10.1016/s0020-7519(02)00194-7